HTA for pharmaceuticals in Europe: will the mountain deliver a mouse? Livio GarattiniAnna Padula Editorial 22 August 2019 Pages: 1 - 5
Cost–consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma Laura Amanda Vallejo-AparicioJesús MolinaHenrik Svedsater Original Paper Open access 23 September 2019 Pages: 7 - 17
The income gradient and child mental health in Australia: does it vary by assessors? Rasheda KhanamSon NghiemMaisha Rahman Original Paper 04 September 2019 Pages: 19 - 36
Speeding up the clinical pathways by accessing emergency departments Rosella LevaggiMarcello MontefioriLuca Persico Original Paper 31 August 2019 Pages: 37 - 44
The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis Axel SvedbomJohan DalénSumesh Kachroo Original Paper 14 September 2019 Pages: 45 - 54
Provision of health care services and regional diversity in Germany: insights from a Bayesian health frontier analysis with spatial dependencies Rouven Edgar HaschkaKatharina SchleyHelmut Herwartz Original Paper 06 September 2019 Pages: 55 - 71
A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction Svenn Alexander HansenEline AasOddvar Solli Original Paper 11 September 2019 Pages: 73 - 84
Inefficiencies in a healthcare system with a regulatory split of power: a spatial panel data analysis of avoidable hospitalisations in Austria Anna-Theresa Renner Original Paper Open access 09 September 2019 Pages: 85 - 104
Global budget versus cost ceiling: a natural experiment in hospital payment reform in the Netherlands Katalin GasparFrance PortraitXander Koolman Original Paper Open access 16 September 2019 Pages: 105 - 114
Economic burden of blindness and visual impairment in Germany from a societal perspective: a cost-of-illness study Yuliya ChuvarayanRobert P. FingerJuliane Köberlein-Neu Original Paper 06 September 2019 Pages: 115 - 127
Does external reference pricing deliver what it promises? Evidence on its impact at national level Panos KanavosAnna-Maria FontrierOlina Efthymiadou Original Paper Open access 03 October 2019 Pages: 129 - 151
Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations Marscha S. HollemanMaiwenn J. AlCarin A. Uyl-de Groot Original Paper Open access 20 September 2019 Pages: 153 - 164